Product center

Abdi Ibrahim Remede Pharma operates from a cutting-edge 5,000 m² R&D center and a 34,000 m² state-of-the-art, large-scale manufacturing facility, offering capabilities from gram-scale to tonne-scale production. Abdi Ibrahim Remede Pharma has successfully developed thousands of mid- to high-end biopharmaceutical products.

Abdi Ibrahim Remede Pharma is a premier supplier of PEG derivatives (mPEGs), offering an extensive portfolio that includes thousands of PEG derivatives, spanning monodispersed and polydispersed structures with molecular weights ranging from 200 to 40,000. Our diverse array of functional groups includes active esters, maleimides, sulfhydryl, amino, azide, phospholipids, fluorescein, and more. We specialize in providing bespoke PEGylation solutions, including site-specific modification, dual linker construction, and multi-active site drugs, ensuring high-quality products and services for a broad spectrum of applications such as long-acting targeted drug delivery, medical device enhancement, diagnostic analysis, aesthetic surgery, and 3D printing.

Abdi Ibrahim Remede Pharma provides comprehensive support to our clients in rapidly defining synthesis routes and optimizing processes for marketed drugs. We offer development of new processes and scale-up services that either improve upon existing methods or are crafted to avoid patent infringement. Our services include process route screening, experimental study design, process development and optimization, impurity synthesis and characterization, technology transfer services, and scaling from milligram to ton levels.

At Abdi Ibrahim Remede Pharma, we operate our own raw material production facility, backed by a production management team with decades of experience in plant operations and management. This expertise ensures the cost-effective, swift, and high-quality production of diverse products tailored to customer specifications. Our facilities are equipped for specialized reactions, including high-temperature and high-pressure processes, as well as low-temperature continuous-flow reactions, enabling the production of a wide range of customer-specific, high-performance products. We excel in producing various pharmaceutical intermediates, such as intermediates for carfilzomib, baloxavir marboxil, etc., from gram to metric ton scale.

Lipid Nanoparticles (LNPs) are critical delivery systems in the realm of nucleic acid-based drugs, including mRNA COVID-19 vaccines, which are composed of four main components: a neutral phospholipid, cholesterol, a polyethylene-glycol (PEG)-lipid, and an ionizable cationic lipid. PEG enhances the stability and longevity of LNPs. As a leader in PEG derivatives, Abdi Ibrahim Remede Pharma offers a comprehensive range of PEG derivatives in both GMP and non-GMP standards, capable of producing and supplying the essential excipients for COVID vaccines in quantities ranging from small to large scale.

Abdi Ibrahim Remede Pharma brings together expert domestic and international teams, utilizing advanced preparation technologies to specialize in both innovative and generic drug development. We excel in process scale-up, technology transfer and optimization, lifecycle management, quality development, and registration declaration support. Our professional team leverages dedicated technology to address development and manufacturing challenges for global pharmaceutical companies. We empower our clients to rapidly progress and market their new drugs, offering comprehensive development and manufacturing services.